therivabio.com (TOVX): Price-to-Projected Revenue Ratio

TOVX (Theriva Biologics Inc) - company brandmark

Theriva Biologics, Inc. (TOVX) is integrating AI models and automation into the development of immunotherapy, with business success relying on the efficacy of viral tumor treatments. A key milestone was the implementation of closed bioreactors to eliminate media contamination. The forward P/S multiple illustrates market expectations, with the metric currently at 21.20, determining the valuation of the company's future sales.

TOVX Theriva Biologics Inc: Market Cap to Future Revenue Ratio in the range 05/08/2026 - 11/18/2026

Analytical breakdowns for Theriva Biologics, Inc. (TOVX)

- stock exchange capitalization data:
Summary company analysis:therivabio.com TOVX
Manufactured products of Theriva Corp

Theriva Biologics, Inc. (TOVX) success in developing immunotherapeutic platforms to combat tumors in partnership with pharma behemoths determines the issuer's future cash flows. By analyzing the forward revenue multiple, an investor assesses the ratio of current market value to expected sales, which allows for an evaluation of the growth rates priced in and the degree of the stock's resilience to market volatility.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|CUE - Forward Price-to-Revenue Multiple|PDSB - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Sonnet BioTherapeutics Holdings SONN|MAIA: Forward P/S Multiple|LIMN - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple LVTX|Market Cap to Projected Revenue NXTC (NextCure)|Price-to-Projected Revenue Ratio leaptx.com (LPTX)|INTS - Market Cap to Future Revenue Ratio|Forward P/S Multiple SNSE (Sensei Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP